<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33643">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117219</url>
  </required_header>
  <id_info>
    <org_study_id>D4190C00007</org_study_id>
    <nct_id>NCT02117219</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate MEDI4736</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity
      of MEDI4736 in subjects with myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets
      programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and
      antitumor activity of MEDI4736 in adult patients with myelodysplastic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subject's safety where no more than one out of six subjects experience DLTs at a given dose.</measure>
    <time_frame>455 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DLT assessment will be done by reviewing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, physical examinations, and electrocardiogram (ECG) results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome in terms of response: duration of response</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>As defined by IWG 2006 MDS response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome in terms of response: transfusion requirements</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>As defined by IWG 2006 MDS response criteria and incidence of transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome in terms of response: progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>As defined by IWG 2006 MDS response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome in terms of response: survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>As defined by IWG 2006 MDS response criteria and collection of survival data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MEDI4736 concentrations in serum: peak concentration</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak concentration of MEDI4736 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MEDI4736 concentrations in serum: area under the concentration-time curve</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MEDI4736 concentration in serum: clearance</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of MEDI4736 clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MEDI4736 concentration in serum: terminal half-life</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>MEDI4736 concentration terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine by number of subjects who develop ADA (anti-drug antibody).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AML (Acute Myeloid Leukemia) transformation</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of AML transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QOL): disease- and treatment-related symptoms</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of reporting of disease- and treatment-related symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QOL): pain</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of incidence of pain reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QOL): health status</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of reporting of health status.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>MEDI4736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate MEDI4736 in MDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>MEDI4736 will be administered by IV infusion</description>
    <arm_group_label>MEDI4736</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult male or female subjects with pathologically confirmed MDS who failed to respond,
        relapsed after an initial response, or were unable to tolerate hypomethylating agents,
        ECOG performance status of 0 - 2, and adequate organ and marrow function.

        Exclusion Criteria:

        Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
        treatment, prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical
        transplant, current immunosuppressive medication or autoimmune or inflammatory disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyson Karakunnel, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Kacprowicz</last_name>
    <phone>301-398-0000</phone>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
